Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO) (HF879026)

Name: Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Brand: abinScience
SKU: HF879026
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HF879026
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1, kappa
Biological activity	Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2]. The elimination half-life (t 1/2) of Adalimumab is long (~20 days) [1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P01375
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	ABP501, D2E7, Adalimumab, AdalimumabBeta, 331731-18-1
Background	Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. TNFa is the therapeutic target of adalimumab (Humira). 1. Nie, H. et al. (2013) Nature medicine 19, 322-8. PMID: 23396208 2. Friedmann, E. et al. (2006) Nature cell biology 8, 843-8. PMID: 16829952 3. Jinesh G, G. et al. (2012) Journal of leukocyte biology 92, 233-44. PMID: 22517918 4. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819
References	1. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [HF879026] 2. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. [HF879026]
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SEC-HPLC

SEC-HPLC detection for Research Grade Adalimumab.
Bioactivity

Detects Human TNFa/TNF-alpha in indirect ELISAs.
Flow Cytometry

Flow-cytometry using anti-human TNFa antibody. 293T Transtected cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human TNFa monoclonal antibody (Catalog HF879026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
SDS-PAGE

SDS-PAGE for Research Grade Adalimumab.